title: Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia.
abstract: Residual immune activation was studied in 51 HIV-infected individuals, 16 with viral load between 1 and 20 copies/ml and 35 with viral load less than 1 copy/ml, and compared with results in 20 healthy blood donors. Higher T-cell activation and IP-10/CXCL10, MIG/CXCL9 and sCD14 plasma levels persisted in both HIV+ groups. The proportion of activated HLA-DR+ CD4 T cells was inversely correlated with the CD4 nadir and the current CD4 cell counts.
authors.affiliation: aSorbonne Universités, UPMC Univ Paris 06 bINSERM, U 1135, CIMI cAPHP, Hôpital Pitié Salpêtrière, Département d'Immunologie, Paris, France d Infectious Diseases Department, Sanremo Hospital, Italy and Center of Excellence for Biomedical Research, University of Genoa, Italy eSorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique fINSERM, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique gAP-HP, Hôpital Pitié-Salpêtrière, Maladies Infectieuses et Tropicales hAPHP, Hôpital Pitié Salpêtrière, Laboratoire de Virologie, Paris, France. *Drs Guihot and Dentone contributed equally to this article.
authors.forename: Amélie
authors.initials: A
authors.lastname: Guihot
authors.forename: Chiara
authors.initials: C
authors.lastname: Dentone
authors.forename: Lambert
authors.initials: L
authors.lastname: Assoumou
authors.forename: Christophe
authors.initials: C
authors.lastname: Parizot
authors.forename: Ruxandra
authors.initials: R
authors.lastname: Calin
authors.forename: Sophie
authors.initials: S
authors.lastname: Seang
authors.forename: Cathia
authors.initials: C
authors.lastname: Soulié
authors.forename: Anne-Geneviève
authors.initials: AG
authors.lastname: Marcelin
authors.forename: Vincent
authors.initials: V
authors.lastname: Calvez
authors.forename: Brigitte
authors.initials: B
authors.lastname: Autran
authors.forename: Christine
authors.initials: C
authors.lastname: Katlama
authors.forename: Dominique
authors.initials: D
authors.lastname: Costagliola
authors.forename: Guislaine
authors.initials: G
authors.lastname: Carcelain
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D001782:Blood Donors; D018791:CD4 Lymphocyte Count; D018925:Chemokines / Q000097:blood; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000473:pathology*; D015497:HIV-1 / Q000276:immunology* / Q000302:isolation & purification; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000097:blood; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D019562:Viral Load; D014766:Viremia / Q000188:drug therapy*
chemical_list: D044966:Anti-Retroviral Agents; D018925:Chemokines; D006684:HLA-DR Antigens; D018950:Lipopolysaccharide Receptors